Journal article
ASSOCIATION BETWEEN SERUM ALKALINE PHOSPHATASE AND RESISTANCE TO ERYTHROPOIESIS STIMULATING AGENTS IN CHRONIC KIDNEY DISEASE: A POST-HOC ANALYSIS OF THE HERO TRIAL
SV Badve, EM Pascoe, A Cass, P Clarke, J Coombes, P Ferrari, SP Mcdonald, AT Morrish, E Pedagogos, V Perkovic, D Reidlinger, A Scaria, R Walker, LA Vergara, CM Hawley, DW Johnson
Nephrology | WILEY-BLACKWELL | Published : 2014
DOI: 10.1111/nep.12815
Abstract
BACKGROUND: Pentoxifylline has been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the Handling Erythropoietin Resistance with Oxpentifylline multicentre double-blind, randomized controlled trial. The present sub-study evaluated the effects of pentoxifylline on the iron-regulatory hormone hepcidin in patients with ESA-hyporesponsive CKD. METHODS: This sub-study included 13 patients in the pentoxifylline arm (400 mg daily) and 13 in the matched placebo arm. Hepcidin-25 was measured by ultra performance liquid chromatography/quadrupole time-of-flight mass spectrometry following isolation fr..
View full abstract